The economics of adalimumab for ulcerative colitis

References

• Ordas I , Eckmann L , Talamini M , et al. Ulcerative colitis. Lancet 2012;380:1606-19
   PubMed Web of Science ®Google Scholar
• Herrinton LJ , Liu L , Lewis JD , et al. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastroenterol 2008;103:1998-2006
   PubMed Web of Science ®Google Scholar
• Manninen P , Karvonen AL , Huhtala H , et al. The epidemiology of inflammatory bowel diseases in Finland. Scand J Gastroenterol 2010;45:1063-7
   PubMed Web of Science ®Google Scholar
• Rutgeerts P , Sandborn WJ , Feagan BG , et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
   PubMed Web of Science ®Google Scholar
• Suzuki Y , Motoya S , Hanai H , et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol 2014;49:283-94
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Van AG , Reinisch W , et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65
   PubMed Web of Science ®Google Scholar
• Sandborn WJ , Colombel JF , D’Haens G , et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013;37:204-13
   PubMed Web of Science ®Google Scholar
• Reinisch W , Sandborn WJ , Hommes DW , et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
   PubMed Web of Science ®Google Scholar
• Reinisch W , Sandborn WJ , Panaccione R , et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis 2013;19:1700-9
   PubMed Web of Science ®Google Scholar
• Garcia-Bosch O , Gisbert JP , Canas-Ventura A , et al. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome. J Crohns Colitis 2013;7:717-22
   PubMed Web of Science ®Google Scholar
• McDermott E , Murphy S , Keegan D , et al. Efficacy of adalimumab as a long term maintenance therapy in ulcerative colitis. J Crohns Colitis 2013;7:150-3
   PubMed Web of Science ®Google Scholar
• Colombel Md JF , Sandborn Md WJ , Ghosh MS , et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: data from ULTRA 1, 2, and 3. Am J Gastroenterol 2014;109(11):1771-80
   PubMed Web of Science ®Google Scholar
• Thorlund K , Druyts E , Mills EJ , et al. Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naive to anti-TNF therapy: an indirect treatment comparison meta-analysis. J Crohns Colitis 2014;8:571-81
   PubMed Web of Science ®Google Scholar
• Stidham RW , Lee TC , Higgins PD , et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014;39:660-71
   PubMed Web of Science ®Google Scholar
• Afif W , Leighton JA , Hanauer SB , et al. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 2009;15:1302-7
   PubMed Web of Science ®Google Scholar
• Armuzzi A , Biancone L , Daperno M , et al. Adalimumab in active ulcerative colitis: a ‘real-life’ observational study. Dig Liver Dis 2013;45:738-43
   PubMedGoogle Scholar
• Oussalah A , Laclotte C , Chevaux JB , et al. Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience. Aliment Pharmacol Ther 2008;28:966-72
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L , Laclotte C , Roblin X , Bigard MA . Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007;13:2328-32
   PubMed Web of Science ®Google Scholar
• Taxonera C , Estelles J , Fernandez-Blanco I , et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011;33:340-8
   PubMed Web of Science ®Google Scholar
• Solberg IC , Lygren I , Jahnsen J , et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009;44:431-40
   PubMed Web of Science ®Google Scholar
• Monstad I , Hovde O , Solberg IC , Moum A . Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol 2014;27:95-104
   PubMedGoogle Scholar
• Reich KM , Chang HJ , Rezaie A , et al. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014;40:629-38
   PubMed Web of Science ®Google Scholar
• Lofland JH , Mallow P , Rizzo J . Cost-per-remission analysis of infliximab compared to adalimumab among adults with moderate-to-severe ulcerative colitis. J Med Econ 2013;16:461-7
   PubMedGoogle Scholar
• Xie F , Blackhouse G , Assasi N , et al. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis. Cost Eff Resour Alloc 2009;7:20
   PubMedGoogle Scholar
• Ali T , Skup M , Yang M , et al. Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis. Annual Scientific Meeting of American College of Gastroenterology, Las Vegas, NV; October 23, 2012
   Google Scholar
• van der Valk ME , Mangen MJ , Leenders M , et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFalpha therapy: results from the COIN study. Gut 2014;63:72-9
   PubMed Web of Science ®Google Scholar